small win: hepatic fat stopped being a problem at week 91
Check-in as promised in the title: small win: hepatic fat stopped being a problem at week 91.
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.
Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.
How fast was the escalation in that protocol?
Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.
the weight numbers are secondary to what this is being developed for
dual GLP-1 and glucagon agonist, and the glucagon arm is the story
Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.
Agreed that the endpoint definitions matter enormously and almost nobody reads them before quoting a response rate.
Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis wit
Disagreeing with this bit: that number comes from a different programme with a different population.
Are you reading the publication or a summary?
Yes — nothing containing this is approved anywhere, which is the first fact and usually the last one mentioned.
Yes — histological endpoints are a far harder bar than the surrogate measures people are used to quoting.
Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.
read the histology endpoint definitions before quoting a response rate
read the histology endpoint definitions before quoting a response rate
Adding the standing caveat — unapproved compound, research material is not for human use.
The escalation schedules in the published protocols are slow and deliberate, and the tolerability tables show why. That is a description of the trials rather than a suggestion for anybody.
Independent result logged. There are almost none for this compound, so it is genuinely valuable.
phase 2 in liver disease is a different evidence question from weight
That is an escalation schedule for an unapproved compound and this board does not host those.
research material is not approved for human use, which is why the clinical record here is thin
a liver endpoint is not a weight endpoint with better marketing
fibrosis improvement without worsening steatohepatitis is the phrase to learn
Has anyone posted an independent purity result for this compound?
Biopsy-confirmed population or imaging-selected?
not approved anywhere, and the boards forget that constantly
this board is small because the compound is early
the titration in the trials was slow and deliberate
- 1How fast was the escalation in that protocol?9 comments in this branch · started by u/farid_kuipers
- 2The escalation schedules in the published protocols are slow and deliberate,…8 comments in this branch · started by u/kaia_cabrera